Girardin 2021.

Study characteristics
Notes	English title Contribution of pulmonary diseases to COVID‐19 mortality in a diverse urban community of New York Study setting Start of study recruitment (MM/YYYY) 03/2020 End of study recruitment (MM/YYYY) 05/2020 Study design registry data Study centre(s) multiple centres/clinics/areas within a country Number of centres/clinics/areas NR Study setting inpatient Number of participants recruited 4446 Sampling method consecutive participants Participants Female participants (absolute number), 1766 Age measure, value mean (standard deviation), 62 (18.89) Inclusion criteria We included only patients with confirmed COVID‐19  who had been discharged alive or had died. Exclusion criteria omitting hospitalised patients with unknown state information Smoking NR Diabetes (absolute number), 1473 Hypertension (absolute number), 2390 Cardiovascular diseases (absolute number), 580 Please indicate if additional information is available  CAD Asthma (absolute number), 493 Chronic obstructive pulmonary disease (absolute number), 329 Other pulmonary diseases (unspecified) Please indicate if additional information is available  NR Immunosuppression (unspecified) Please indicate if additional information is available NR Chronic kidney disease (unspecified) Cancer (absolute number), 472 Steroid administration (unspecified) Supplemental oxygen (unspecified) Differential values for various oxygenation methods (if indicated) NR Other treatment unspecified Dose if applicable NR Duration if applicable NR Percentage received this treatment NR Prognostic factor(s) Study’s definition for obesity NR The time when obesity has been measured before disease or right at presentation Main variable used for determination of obesity BMI Threshold used for definition of obesity  NR Measure of frequency absolute number Frequency value 1660 How many eligible outcomes reported? 1 How many eligible outcomes reported? 1 Outcome(s) mortality Outcome (prognostic factor) Mortality (obesity NS) Outcome Mortality  Prognostic factor (category):  Obesity NS  Follow‐up Number of patients followed completely for this outcome  4210 Number of obese patients followed completely for this outcome  1660 Number of non‐obese patients followed completely for this outcome  2550 Univariable (unadjusted) analysis for obesity Effect measure for obesity NR Effect measure value (95% CI) NR Multivariable (adjusted) analysis for obesity Modelling method Cox regression The set of prognostic factors used for adjustment Age, ethnicity, gender, income, smoking, obesity, COPD, asthma, sleep apnoea, HTN, hlp, DM, CAD, PAD, autoimmunity, cancer Effect measure for obesity hazard ratio Effect measure value (95% CI) 1.19 (1.04, 1.37)
Item	Authors' judgement	Support for judgement
Study Participation	Yes	Appendix 3
Study Attrition Mortality	Yes	Appendix 3
Prognostic Factor Measurement	No	Appendix 3
Outcome Measurement Mortality	Yes	Appendix 3
Confounding Bias Mortality	Unclear	Appendix 3
Statistical Analysis Bias	Unclear	Appendix 3